A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma Read more
Identification of Novel Metabolomics and MRI Based Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity Following Treatment for Thoracic Malignancies Read more
Phase III randomized and double-blinded trial of de-escalated radiation in FMISO PET-selected good risk versus standard of care radiation in unselected HPV positive oropharyngeal cancer Read more
Determining the proportion of Cancer Center patients with certain diagnoses over the last two years who would be eligible for treatment with RefleXion Scintix technology. Read more
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Read more
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) Read more
A phase I, open-label, multicenter study to assess safety, tolerability, PK and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with KRASG12C mutant advanced solid tumors Read more
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer Read more
